This study aims to compare the antimicrobial activity of omadacycline with tigecycline against clinical isolates of Enterococcus faecium and investigate their resistance mechanisms. Non-duplicate clinical E. faecium isolates (n = 224) were collected and the minimal inhibitory concentrations (MICs) of omadacycline and tigecycline were determined by broth microdilution method. The tet genes and the genetic mutations in 16 S rRNA genes and 30 S ribosomal protein S10 were determined by PCR and sequence alignment. The global protein abundances of the omadacycline-induced and parent isolates were determined by a Q Exactive plus mass spectrometer. The MIC/MIC of omadacycline and tigecycline against the 224 E. faecium isolates were 0.25/0.5 mg l and 0.125/0.25 mg l, respectively. Among these E. faecium isolates, the frequency of the isolates with omadacycline MICs ≥ 0.25 mg l were significantly higher than that with tigecycline MICs ≥ 0.25 mg l. Moreover, the T1473C and/or G1468A mutations in the 16 S rRNA and Lys98Glu mutation in the 30 S ribosomal protein S10 were identified in the 3 series of tigecycline or omadacycline- nonsusceptible isolates selected in vitro. The abundances of 32 proteins changed in the omadacycline-induced isolate, of which 10 increased and 22 decreased. The abundance of tet(M) increased significantly in the omadacycline-induced isolate, and the abundance of proteins included in cellular process and metabolic process decreased. In conclusion, Omadacycline and tigecycline exhibits excellent activities against clinical isolates of E. faecium and exposure to omadacycline and tigecycline can result in significant cross-resistance to both antibiotics. The high-level expression of tet(M) in E. faecium may confer resistance to omadacycline.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/s41429-022-00538-2 | DOI Listing |
Diagn Microbiol Infect Dis
December 2024
Department of Medical Microbiology, Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Nontuberculous mycobacteria (NTM) are emerging opportunistic pathogens with limited treatment options due to resistance to multiple antibiotic classes. This study aimed to evaluate the in vitro activity of omadacycline and comparator antibiotics against rapidly growing mycobacteria (RGM) clinical isolates. Minimum inhibitory concentration (MIC) evaluation of RGM clinical isolates was performed by two independent laboratories (EU and Japan).
View Article and Find Full Text PDFCureus
December 2024
Internal Medicine, University of Maryland Medical Center, Baltimore, USA.
When bacteria are tetracycline- or doxycycline-resistant, the ability of these bacteria to be susceptible to the other tetracyclines is not well defined. Consequently, gaining knowledge about the ability to infer Enterobacterales susceptibility to minocycline and third-generation tetracycline antibiotics from surrogates is vital. In this study, we show that tigecycline may be a reasonable surrogate from which clinicians can infer omadacycline and eravacycline susceptibilities, even in the presence of doxycycline and tetracycline resistance.
View Article and Find Full Text PDFJ Antibiot (Tokyo)
December 2024
Department of Respiratory Medicine, An Qiu People's Hospital, An Qiu, China.
Therapeutic options for carbapenem-resistant Acinetobacter baumannii (CA-AB) are quite limited. Cefiderocol, a novel siderophore cephalosporin, has shown potent in vitro activity against CR-AB, and new tetracycline analogues such as eravacycline and omadacycline have been available in recent years. However, the synergism of cefiderocol with tetracycline analogues against CR-AB has not been well investigated.
View Article and Find Full Text PDFJ Mass Spectrom Adv Clin Lab
November 2024
Department of Pharmacy, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Objective: We aimed to develop a rapid, simple, and precise ultra performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) technique for simultaneous measurement of omadacycline (OMA) and tigecycline (TGC) in the bloodstream of individuals suffering from serious bacterial infections.
Methods: All analytes were extracted using a 0.2 % formic acid-water dilution and acetonitrile plasma protein precipitation.
Biomed Pharmacother
December 2024
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain; Ciber de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Introduction: The rise in multidrug-resistant bacteria challenges clinical microbiology. Tigecycline, eravacycline, and omadacycline show promise against carbapenem-resistant Enterobacterales and Acinetobacter baumannii. This study evaluates their activity and resistance mechanisms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!